insights_auto
Why is DMN down ५.११%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
€ ०.०५९
arrow_downward
-५.११%(-०.००३२) 1D
नोभेम्बर २०, २२:००:०० GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.४७ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.४७ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
The Motley Fool
·
४५ मिनेट पहिले
Report: Goldman Sachs Predicts the S&P 500 Will Gain 26% in 12 Months
marketscreener.com
·
५७ मिनेट पहिले
Nasdaq has its worst week since 2020; Dow, S&P 500 in correction
WXOW
·
५९ मिनेट पहिले
S&P 500 sinks 3.7% and the Nasdaq composite goes negative for the year
FXStreet
·
४ घण्टा पहिले
Dow Jones Industrial Average drops for a fifth day as AI rout widens
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB